Alpha Tau Stock Rallies To 3-Month High On Smaller-Than-Feared Q1 Loss: Retail Sentiment Stays Bearish

Alpha Tau Medical Ltd. shares hit their highest level on Monday in three months following the company's report of a smaller-than-expected quarterly loss and advances in several U.S. FDA-approved clinical trials.

The stock rose 11.1% to close at $3.10 and extended gains by another 6.5% to $3.30 in after-hours trading.

For the first quarter ending March 31, the company posted a net loss of $8.7 million, equivalent to $0.12 per share, widening from a loss of $8.0 million or $0.11 per share a year earlier.

According to The Fly, analysts expected Alpha Tau Medical to report a bigger loss of $0.13 per share.

The company's financial income rose to $0.7 million from $0.4 million in the previous year due to reduced warrant remeasurement expenses, offsetting the decrease in interest income from deposits.

Alpha Tau's regulatory achievements, including four active FDA Investigational Device Exemptions (IDEs) and upcoming U.S. trials for pancreatic cancer along with recurrent glioblastoma multiforme (GBM), generated positive investor response, which led to share price increases even though financial losses continued.

CEO Uzi Sofer said that 2025 started with significant milestones, such as facility expansion in New Hampshire and strong clinical advancements, which received support from a $36.9 million capital increase.

On Stocktwits, retail sentiment was ‘bearish’ amid ‘high’ message volume.

The stock has remained flat so far in 2025.

For updates and corrections, email newsroom[at]stocktwits[dot]com.